[go: up one dir, main page]

WO2006114054A1 - Utilisation d’amorphophallus rivieri durieu et d’un extrait de celui-ci dans la fabrication d’un medicament pour le traitement de la bronchite aigue, chronique - Google Patents

Utilisation d’amorphophallus rivieri durieu et d’un extrait de celui-ci dans la fabrication d’un medicament pour le traitement de la bronchite aigue, chronique Download PDF

Info

Publication number
WO2006114054A1
WO2006114054A1 PCT/CN2006/000786 CN2006000786W WO2006114054A1 WO 2006114054 A1 WO2006114054 A1 WO 2006114054A1 CN 2006000786 W CN2006000786 W CN 2006000786W WO 2006114054 A1 WO2006114054 A1 WO 2006114054A1
Authority
WO
WIPO (PCT)
Prior art keywords
konjac
extract
ethanol
schisandra
pharmaceutical composition
Prior art date
Application number
PCT/CN2006/000786
Other languages
English (en)
Chinese (zh)
Inventor
Shuhua Zhu
Original Assignee
Shuhua Zhu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shuhua Zhu filed Critical Shuhua Zhu
Priority to JP2008508055A priority Critical patent/JP5265347B2/ja
Priority to KR1020077027668A priority patent/KR101452394B1/ko
Publication of WO2006114054A1 publication Critical patent/WO2006114054A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/882—Acoraceae (Calamus family), e.g. sweetflag or Acorus calamus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Definitions

  • the present invention relates to a novel use of a medicament, in particular, to the use of konjac in the preparation of a medicament for the treatment of chronic bronchitis.
  • Chronic bronchitis is common in winter and spring, and it is a frequently-occurring disease and common disease. It is susceptible to the disease in people over 40 years old. 1998. According to national statistics, chronic bronchitis is 9.7% in rural areas, 12.4% in urban areas, with an average of 11.05%, and about 18% in middle-aged and elderly people over 40 years old. In 2003, cities accounted for 8.2%, rural areas accounted for 7.75%, and middle-aged people under 40 years old. About 15% of people. At present, western medicine for treating chronic bronchitis uses symptomatic treatment for this disease, which lacks an overall concept and is not easy to heal. The traditional Chinese medicines for the treatment of chronic bronchitis and the combination of Chinese and Western medicines have the following problems: 1.
  • the antitussive, antiasthmatic and expectorant effects need to be taken for a long time. If the drug is discontinued, the condition will recur quickly; 2. Most of these drugs contain anesthesia.
  • Some proprietary Chinese medicines for treating chronic bronchus have certain side effects, which can only cure the symptoms and cannot cure the disease.
  • the technical proposal of the present invention provides a new use of a medicinal material, in particular, the use of konjac in the preparation of a medicament for treating chronic bronchitis, and another technical solution of the present invention provides a pharmaceutical composition containing konjac in a raw material. And its preparation method and use.
  • the present invention provides the use of konjac and its extract (Amorphophallus rivieri Durieu) for the preparation of a medicament for the treatment of acute and chronic bronchitis.
  • the konjac extract is a konjac ethanol extract or an organic solvent extract.
  • the organic solvent is diethyl ether, methanol, ethyl acetate, petroleum ether, n-hexane.
  • the konjac ethanol extract is a 25% to 95% ethanol extract. Further, the konjac ethanol extract is 60% to 95% ethanol extract, preferably 80% to 95% ethanol extract.
  • the present invention also provides a pharmaceutical composition which is prepared by using konjac and its extract as an active ingredient or a raw material, together with a pharmaceutically acceptable adjuvant or auxiliary ingredient.
  • the raw material further contains Schisandra, and the weight ratio thereof is - Konjac: Schisandra 1 ⁇ 10: 9 ⁇ 0, wherein the weight ratio of Schisandra cannot be 0.
  • the agent is a capsule, a granule, a tablet, a pill, or an oral solution.
  • each capsule of the capsule contains not less than 1.8 mg of schisandrin.
  • the invention also provides a preparation method of the pharmaceutical composition, which comprises the following steps:
  • the ethanol extraction method described in the step b is an ethanol percolation method, the ethanol concentration is 60% to 95%; the percolation rate is 1 ml/min ⁇ kg; and the alcohol concentration in the step c is 70%. Further, the ethanol extraction method described in the step b is an ethanol percolation method, and the ethanol concentration is 60%.
  • the invention also provides the use of the pharmaceutical composition for the preparation of a medicament for the treatment of acute bronchitis, chronic bronchitis, emphysema, pulmonary heart disease and symptoms thereof.
  • the main clinical symptoms of pulmonary heart disease are long-term cough, sputum and varying degrees of dyspnea, especially after activity or during the cold season.
  • the patient may have no symptoms when he is quiet. If he is slightly active, he may have shortness of breath, shortness of breath, palpitations, pain in the precordial area, fatigue, chest tightness and other symptoms.
  • the schisandra chinensis in the raw material group of the invention has the functions of benefiting Qi, nourishing kidney, relieving asthma, relieving cough, phlegm, stimulating, sweating, phlegm, diarrhea and the like, and is a treatment for cough and asthma, especially lung qi deficiency and lung. An important drug with kidney deficiency and cough and asthma.
  • the main cough is up against the gas, the qi deficiency is on the sputum and not on the yuan.
  • the gas is returned to the yuan, then the cough is reversed from the gas.
  • "Materia Medica” thinks: “Where the qi deficiency is anxious, the cough is strained, the spirit is insufficient... The schisandra is used to treat it. Concentrate on Shengjin, to protect the vitality without leaving any suffocation. "Although it is appropriate to use deficiency syndrome and cough, but this virtual standard is also quite common.
  • the schisandra supplements the lungs, and can be aimed at the lung qi deficiency and the main gas, the main line of water, the main sacral hair loss, the main fur and other functions caused by short-term, fatigue, It is easy to feel the external evils, sputum is easy to store the lungs and the lungs are reversed. It is also used to relieve cough, asthma and phlegm, and effectively relieve symptoms such as cough, asthma and phlegm. Konjac is prepared into various preparations by the drug production process of the present invention, and is non-irritating and safe to the mouth, tongue, throat and the like.
  • the raw materials of konjac and schisandra are used in combination, which is a combination of the righteousness and the evil spirits.
  • the specimens are taken care of.
  • ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ It has the functions of nourishing the lungs and kidneys, relieving cough, relieving asthma and phlegm.
  • chronic bronchitis which are lung qi deficiency or lung and kidney deficiency, and have cough, wheezing and sputum, they can not only relieve their phlegm, asthma and phlegm. If the symptoms are to cure the symptoms, it can help the lungs and kidneys to cure the disease, and it is reliable for chronic bronchitis.
  • the konjac of the invention is used alone or in combination with other drugs, has clinical curative effect, is safe, stable, and controllable, and provides a new choice for clinical treatment of acute and chronic bronchitis.
  • the schisandra was pulverized into a coarse powder, and refluxed with 70% ethanol for 2 times; the konjac was pulverized into a coarse powder, 60% ethanol was percolated, and the percolation rate was lml/min * kg, and the percolate was collected.
  • the schisandra chinensis reflux extract and the konjac osmosis solution are combined, the ethanol is recovered under reduced pressure, and concentrated to a clear paste under reduced pressure, and an appropriate amount of auxiliary materials are added, spray-dried, and granulated by a thousand methods, and then obtained by capsule filling.
  • the schisandra was pulverized into a coarse powder, and extracted with 25% ethanol under reflux for 2 times; the konjac was pulverized into a coarse powder, 60% ethanol was percolated, and the percolation rate was 10 ml/min ⁇ kg, and the percolate was collected.
  • the schisandra chinensis reflux extract and the konjac osmosis solution are combined, and the ethanol is recovered under reduced pressure, and concentrated to a clear paste under reduced pressure.
  • the appropriate amount of auxiliary materials is added, spray-dried, dry granulation, and capsules are obtained.
  • the schisandra was pulverized into a coarse powder, and extracted with 95% ethanol under reflux for 2 times; the konjac was pulverized into a coarse powder, and 95% ethanol was added for percolation, and the percolation rate was 0.5 ml/min ⁇ kg, and the percolate was collected.
  • the schisandra chinensis reflux extract and the konjac osmosis solution are combined, the ethanol is recovered under reduced pressure, and concentrated to a clear paste under reduced pressure, and an appropriate amount of auxiliary materials are added, spray-dried, dry granulation, and capsules are obtained.
  • Raw materials Schisandra 1150 g , Konjac 1150 g , excipients: micronized silica gel, starch, dextrin, microcrystalline cellulose, lactose or a mixture thereof, appropriate amount, the preparation method is the same as in the first embodiment.
  • Raw materials Schisandra 560 g , Konjac 2240g, excipients: micronized silica gel, starch, dextrin, microcrystalline cellulose, lactose or a mixture thereof, appropriate amount, the preparation method is the same as in the first embodiment.
  • Raw materials Schisandra 480g, Konjac 2400 g , Excipients: Micronized silica gel, starch, dextrin, microcrystalline cellulose, lactose or a mixture thereof, appropriate amount, the preparation method is the same as in Example 3, granulation, tableting, that is.
  • Raw materials Schisandra 420 g , Konjac 2520 g , excipients: micronized silica gel, starch, dextrin, microcrystalline cellulose, lactose or a mixture thereof, appropriate amount
  • the preparation method is the same as in the first embodiment, granulation, whole grain, that is, obtained.
  • Raw materials Schisandra 330g, Konjac 2640g, excipients: micronized silica gel, starch, dextrin, microcrystalline cellulose, lactose or a mixture thereof, appropriate amount, the preparation method is the same as in the first embodiment.
  • Raw materials Schisandra 300g, Konjac 2700 g , excipients: micronized silica gel, starch, dextrin, microcrystalline cellulose, lactose or a mixture thereof, appropriate amount, the preparation method is the same as in Example 3.
  • Raw materials Konjac 3300 g , excipients: micronized silica gel, starch, dextrin, microcrystalline cellulose, lactose or a mixture thereof, the appropriate amount, the preparation method is the same as in the first embodiment.
  • Example 1-13 The content of lg prepared by any of the methods of Example 1-13 was added, and 30 ml of chloroform was added thereto, sonicated for 30 minutes, filtered, and the filtrate was evaporated to dryness. The residue was dissolved in methanol (1 ml) to dissolve. Another schisandra alcohol and five flavors As a reference solution, a solution of lm g per lml was prepared by adding methanol to a reference substance.
  • Quantitative determination Determined by high performance liquid chromatography (Chinese Pharmacopoeia 2000 edition, an appendix VID).
  • Chromatographic conditions and system suitability test octadecyl silicon germanium bonded silica as a filler; methanol-water (volume ratio 65: 35) as mobile phase; detection wavelength is 250 nm.
  • the number of theoretical plates should be no less than 3000 according to the peak of schisandra alcohol.
  • Preparation of reference solution Accurately weigh the appropriate amount of Schisandrin A reference substance, add methanol to make a solution containing O.lmg per lml, that is.
  • test solution The contents of the difference prepared by the method of any of Examples 1-13 were finely ground, about 0.8 g , accurately weighed, placed in a 50 ml volumetric flask, and added with methanol 45 ml, sonicated 40 Minutes, take out, place at room temperature, dilute to the mark with methanol, shake well, centrifuge, and take the supernatant.
  • the measurement method accurately absorbs 10 nl of each of the reference solution and the test solution, and injects into the liquid chromatograph, and calculates and obtains.
  • the capsule of the present invention contains not less than 1.80 m g per gram of schisandrin (C 24 H 32 0 7 ).
  • test sample Take 3kg of konjac medicinal material, pulverize it into coarse powder, wet it with petroleum ether (60 90 °C), put it into the osmotic tube, soak it for 24 hours, then collect it by 6 times at the speed of lml/kg, min.
  • mice weighing 18 ⁇ 22 g , male and female were randomly divided into blank control group, konjac A-like group (2g original drug/k g ), B-like group (2 g original drug/k g ), C-like sample.
  • Each group was intragastrically administered daily at a volume of 1 ml/100 g body weight, and the blank control group was given an equal amount of physiological saline for 7 days. 30 minutes after the last administration, each mouse was intraperitoneally injected with 0.5 ml of 0.5% phenol red solution.
  • mice were sacrificed by cervical dislocation, and the trachea and bronchi of the mice were lavaged 3 times with 5% NaHC0 3 solution, 0.5 each time.
  • Ml about 1.5 ml of the lavage fluid was collected, and the absorption value was measured at a wavelength of 520 nm using a 721 spectrophotometer. The results are shown in Table 2.
  • Ammonium chloride group 10 30mg/kg 1.76 ⁇ 0.52* J
  • ammonium chloride group can significantly increase the phenol red emission in the respiratory tract of mice, which is significantly different from the control group.
  • the konjac C dose group can increase the phenol red emission in the respiratory tract of mice, but weaker than the ammonium chloride group. There were also significant differences compared with the control group.
  • the konjac and sputum dose groups also increased the phenol red emission in the respiratory tract of mice, but there was no significant difference compared with the control group.
  • the konjac D dose group had no effect on the phenol red emission in the respiratory tract of mice.
  • the pharmacodynamic experiments of different polar solvent extracts of Konjac showed that:
  • the ethanol extract of konjac flour had obvious pharmacological effects, and the drug had no obvious pharmacological effects, so the ethanol extraction was considered.
  • the konjac was extracted with 95% ethanol, it was extracted by hot reflux and filled into capsules for taking, and 30 cases were observed. Among them: 12 males, 40%; 18 females, accounting for 60%; 26 years old, 26 cases, accounting for 87%; 4 years old, 4 cases, accounting for 13%;
  • Lin Guomin 59 years old, has been taking medicine for 14 years. He has been emphysema when taking the medicine. After taking it, his condition has not recurred. He is 73 years old and is in good health.
  • the following is a pharmacodynamic test of a pharmaceutical composition (prepared as described in Example 1) prepared by using konjac and schisandra as raw materials.
  • the medicament of the invention has a good therapeutic effect on the rat model of chronic bronchitis induced by lipopolysaccharide, and compared with the model group, the dose groups of the present invention can reduce the number of elevated neutrophils and make alveolar macrophages The composition ratio increased, and the high-dose group was significantly different from the model group ( ⁇ ⁇ 0.05). Compared with the normal control group, the neutrophil count and the composition ratio of alveolar macrophages in each dose group of the present invention did not return to normal. 2.
  • the dose groups of the present invention can significantly reduce the number of coughs in mice exposed to ammonia, compared with the control group, there is a significant difference C ⁇ 0.01); the large and medium dose groups of the present invention can significantly reduce tannic acid
  • the number of sputum in guinea pigs was induced (P ⁇ 0.001, P ⁇ 0.05), indicating that it has a strong antitussive effect.
  • the large, medium and small doses of the drug of the present invention can increase the phenol red emission in the respiratory tract of the mice, which is significantly different from the control group ( ⁇ 0.01, corpse ⁇ 0.05).
  • the large, medium and small dose groups of the medicament of the invention can also make rats The amount of sputum increased, compared with the control group, there was a significant difference ( ⁇ . ⁇ , ⁇ ⁇ 0.01) indicating that it had a good sputum effect. 4.
  • the large, medium and small doses of the drug of the present invention can prolong the asthmatic latency of guinea pig asthmatic reaction induced by histamine, and compared with the control group, there is a significant difference ⁇ 0.05, corpse ⁇ 0.01), indicating that it has Certain anti-asthmatic effect.
  • the large, medium and small doses of the drug of the invention can significantly inhibit the swelling reaction of the mouse ear made by xylene, and there is a significant difference compared with the control group ( ⁇ 0.01); the large, medium and small doses of the drug of the invention The group also inhibited the weight of cotton granuloma in mice, compared with the control group, there was a significant difference (P ⁇ 0.05, P ⁇ Q. 0, indicating that it has a good anti-inflammatory effect. 6.
  • the drug of the present invention is large
  • the middle dose group can increase the thymus index, compared with the control group, there is a significant difference (household ⁇ 0.01).
  • the low dose group can also increase the thymus index, compared with the control group, there is a significant difference (corpse ⁇ 0. 05
  • the high-dose group of the present invention can increase the thymus index, and there is a significant difference compared with the control group ( ⁇ . ⁇ ) - the large and medium-dose group of the present invention can promote the production of hemolysin antibody in mice, and the control group Compared, there is a significant difference ( ⁇ ⁇ 0.05), which indicates that it can increase the weight of immune organs in mice, promote the production of hemolysin antibody in mice, and enhance the immune function of the body.
  • the medicament of the present invention has the effects of treating chronic bronchitis as well as antitussive, antispasmodic and antiasthmatic effects, and has certain anti-inflammatory and immune function.
  • the medicinal preparation of the drug of Example 1 is subjected to the following toxicological test, and the result of the acute toxicity test of the mouse is as follows - the acute toxicity test of the drug of the present invention shows that the maximum dose of the drug of the present invention is 182. 4 g of the original drug / kg It is about 456 times of the clinical dose of an adult, and the results show that the drug of the present invention has little acute toxicity.
  • the long-term toxicity test results of the 26-week rat of the present invention showed that the drug of the present invention was administered to the rats in an amount of 45. 6 g of the original drug/kg, 22. 8 g of the original drug/kg, and 11. 4 g of the original drug/kg. (114 times, 57 times, 28. 5 times the clinical dose, respectively).
  • the drug (content) of the present invention has a large dose (4. Og/kg) to give a reaction to the dog after oral administration, and after 1 week, it is adapted and no longer appears.
  • the whole test animal has stool softness and urination with drug color.
  • the weight gain is slower than the other three groups, the dog looks normal, the coat is shiny and lively.
  • Medium (2. Og/kg). No abnormalities were observed in the small (1. Og/kg) dose group.
  • the drug (content) of the present invention is generally observed for 180 days. 4. 0, 2. Og/kg can cause soft stools, urinary tract color, liver enzymes (ALP) index and liver coefficient have risen. Trends, withdrawal observations returned to normal after 30 days, 1. The dose below Og/kg is safe for animals. The above results suggest that the drug (content) of the present invention has greater safety.
  • the drug konjac of the invention is used alone, treating chronic bronchitis, having exact efficacy, low clinical recurrence rate, and being used or compatible with other drugs (such as Schisandra) to achieve synergistic effect. It is safe, stable and controllable, providing a new choice for clinical treatment of acute and chronic bronchitis.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention concerne l’utilisation d’amorphophallus rivieri durieu ou d’un extrait de celui-ci dans la fabrication d’un médicament pour le traitement de la bronchite aiguë, chronique. La présente invention concerne également une composition pharmaceutique comprenant amorphophallus rivieri durieu et fructus schisandrae comme matières premières, et le traitement et l’utilisation de la composition pharmaceutique.
PCT/CN2006/000786 2005-04-27 2006-04-25 Utilisation d’amorphophallus rivieri durieu et d’un extrait de celui-ci dans la fabrication d’un medicament pour le traitement de la bronchite aigue, chronique WO2006114054A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2008508055A JP5265347B2 (ja) 2005-04-27 2006-04-25 急性および慢性気管支炎を治療するための医薬を調合する際の魔芋（こんにゃく芋）およびその抽出物の利用
KR1020077027668A KR101452394B1 (ko) 2005-04-27 2006-04-25 급성 및 만성 기관지염의 치료용 약제의 제조에 있어서곤약 및 그 추출물의 용도

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CNB2005100207991A CN100536883C (zh) 2005-04-27 2005-04-27 魔芋及其提取物在制备治疗急、慢性支气管炎的药物中的用途
CN200510020799.1 2005-04-27

Publications (1)

Publication Number Publication Date
WO2006114054A1 true WO2006114054A1 (fr) 2006-11-02

Family

ID=37194349

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2006/000786 WO2006114054A1 (fr) 2005-04-27 2006-04-25 Utilisation d’amorphophallus rivieri durieu et d’un extrait de celui-ci dans la fabrication d’un medicament pour le traitement de la bronchite aigue, chronique

Country Status (4)

Country Link
JP (1) JP5265347B2 (fr)
KR (1) KR101452394B1 (fr)
CN (1) CN100536883C (fr)
WO (1) WO2006114054A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190125703A (ko) * 2018-04-30 2019-11-07 주식회사 종근당 백출 및 오미자 추출물을 포함하는 진해거담 활성을 갖는 조성물
CN111758768A (zh) * 2020-07-13 2020-10-13 湖南农业大学 一种速冻黄花菜的加工方法及其保鲜存储装置

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104096380B (zh) * 2013-04-15 2017-07-14 天津天士力现代中药资源有限公司 一种高效渗漉提取中药有效成分的方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1033565A (zh) * 1987-12-22 1989-07-05 中国科学院成都生物研究所 一种药用魔芋精粉加工技术
CN1197676A (zh) * 1997-04-27 1998-11-04 李向东 用魔芋制成的卫生敷料及其制法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR19980083461A (ko) * 1997-05-15 1998-12-05 박원훈 혈소판 활성인자 수용체 결합에 대하여 길항활성을 갖는 물질 및 이것을 함유하는 약학적 조성물의 용도
JP4180258B2 (ja) * 2001-08-06 2008-11-12 西川ゴム工業株式会社 ＩｇＥ抗体抑制剤および食品
JP2003081859A (ja) * 2001-09-07 2003-03-19 Taisho Pharmaceut Co Ltd アレルギー性鼻炎治療薬
JP2004043359A (ja) * 2002-07-11 2004-02-12 Unitika Ltd ＩｇＥ抗体産生抑制剤及び花粉症予防・治療剤

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1033565A (zh) * 1987-12-22 1989-07-05 中国科学院成都生物研究所 一种药用魔芋精粉加工技术
CN1197676A (zh) * 1997-04-27 1998-11-04 李向东 用魔芋制成的卫生敷料及其制法

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190125703A (ko) * 2018-04-30 2019-11-07 주식회사 종근당 백출 및 오미자 추출물을 포함하는 진해거담 활성을 갖는 조성물
WO2019212170A1 (fr) * 2018-04-30 2019-11-07 Chong Kun Dang Pharmaceutical Corp. Composition ayant des activités antitussives et d'expectoration comprenant un extrait d'atractylodis rhizoma alba et de schisandrae fructus
KR102202122B1 (ko) 2018-04-30 2021-01-13 주식회사 종근당 백출 및 오미자 추출물을 포함하는 진해거담 활성을 갖는 조성물
CN111758768A (zh) * 2020-07-13 2020-10-13 湖南农业大学 一种速冻黄花菜的加工方法及其保鲜存储装置

Also Published As

Publication number Publication date
JP5265347B2 (ja) 2013-08-14
CN100536883C (zh) 2009-09-09
KR20080005592A (ko) 2008-01-14
KR101452394B1 (ko) 2014-10-21
JP2008539175A (ja) 2008-11-13
CN1853697A (zh) 2006-11-01

Similar Documents

Publication Publication Date Title
CN112587602B (zh) 一种止咳化痰的中药组合物、提取物及其制备方法和应用
CN102764294B (zh) 一种祛痰止咳组合物及其制备方法
WO2006114054A1 (fr) Utilisation d’amorphophallus rivieri durieu et d’un extrait de celui-ci dans la fabrication d’un medicament pour le traitement de la bronchite aigue, chronique
CN101856489B (zh) 猪健颗粒及其制备工艺
CN103751579A (zh) 治疗鼻咽癌放疗引起口腔粘膜炎的药物组合物及其制备方法
CN103041151A (zh) 治疗气管炎的中药组合物及其制备方法
CN102935177B (zh) 一种用于治疗干燥综合症的中药组合物及制备方法和应用
CN1939499B (zh) 吉祥草提取物及其制备方法、药物组合物和用途
CN101919919B (zh) 腹可安分散片及其制备方法
CN1073439C (zh) 一种治疗气管炎、哮喘病的药物及制备方法
CN101711823B (zh) 用于治疗哮喘性支气管炎的药物
CN101190282B (zh) 一种治疗上呼吸道感染的无糖复方中药制剂及其质量控制方法
CN100531765C (zh) 半夏提取物及其制备方法、药物组合物和用途
CN100394947C (zh) 治疗颈椎病的药物组合物及制备方法
CN118557673B (zh) 一种改善胃肠消化功能的中药制剂及其制备方法
CN101653566B (zh) 一种治疗腮腺炎的中药复方制剂
WO2015018123A1 (fr) Préparation de médecine chinoise traditionnelle destiné à réduire le taux de glycémie, et son procédé de préparation
CN102048918A (zh) 一种治疗支气管炎的中药制剂
CN108514627A (zh) 一种治疗慢性荨麻疹的中药组合物
CN109718283B (zh) 一种平喘化痰中药组合物及其制备方法
CN101450157A (zh) 一种治疗慢性支气管炎和哮喘的药物组合物
CN101658624A (zh) 一种治疗慢性支气管炎的中药组合物及其制备方法
CN108938785B (zh) 一种治疗咳嗽变异性哮喘的中药组合物及其制备方法
CN106074904B (zh) 一种治疗放射性口腔黏膜炎的药物组合物及其制备方法
CN118717883A (zh) 一种用于骨关节痛、风湿病、类风湿性关节炎、坐骨神经痛中药组合物及其制备方法、应用和质量控制方法

Legal Events

Date Code Title Description
DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2008508055

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

NENP Non-entry into the national phase

Ref country code: RU

WWE Wipo information: entry into national phase

Ref document number: 1020077027668

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06741717

Country of ref document: EP

Kind code of ref document: A1